Abstract: Successful translation of multipotent mesenchymal stromal cell (MSC)-based therapies into clinical reality relies on adequate cell production procedures. These should be available not only for human MSC, but also for MSC from animal species relevant to preclinical research and veterinary medicine. The cell culture medium supplementation is one of the critical aspects in MSC production. Therefore, we previously established a scalable protocol for the production of buffy-coat based equine platelet lysate (ePL). This ePL proved to be a suitable alternative to fetal bovine serum (FBS) for equine adipose-derived (AD-) MSC culture so far, as it supported AD-MSC proliferation and basic characteristics. The aim of the current study was to further analyze the functional properties of equine AD-MSC cultured with the same ePL, focusing on cell fitness, genetic stability and pro-angiogenic potency. All experiments were performed with AD-MSC from = 5 horses, which were cultured either in medium supplemented with 10% FBS, 10% ePL or 2.5% ePL. AD-MSC cultured with 2.5% ePL, which previously showed decreased proliferation potential, displayed higher apoptosis but lower senescence levels as compared to 10% ePL medium ( < 0.05). Non-clonal chromosomal aberrations occurred in 8% of equine AD-MSC cultivated with FBS and only in 4.8% of equine AD-MSC cultivated with 10% ePL. Clonal aberrations in the AD-MSC were neither observed in FBS nor in 10% ePL medium. Analysis of AD-MSC and endothelial cells in an indirect co-culture revealed that the ePL supported the pro-angiogenic effects of AD-MSC. In the 10% ePL group, more vascular endothelial growth factor (VEGF-A) was released and highest VEGF-A concentrations were reached in the presence of ePL and co-cultured cells ( < 0.05). Correspondingly, AD-MSC expressed the VEGF receptor-2 at higher levels in the presence of ePL ( < 0.05). Finally, AD-MSC and 10% ePL together promoted the growth of endothelial cells and induced the formation of vessel-like structures in two of the samples. These data further substantiate that buffy-coat-based ePL is a valuable supplement for equine AD-MSC culture media. The ePL does not only support stable equine AD-MSC characteristics as demonstrated before, but it also enhances their functional properties.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This study investigated the use of equine platelet lysate (ePL) in culturing equine adipose-derived mesenchymal stromal cells (AD-MSCs), exploring the effects of ePL on cell behavior, genetic stability, and angiogenic potential. It concludes that ePL not only maintains the stable characteristics of equine AD-MSCs but also enhances their functional properties.
Cell Culturing and Adipose-Derived Mesenchymal Stromal Cells
The research highlights the importance of effective cell production procedures in translating the potential of mesenchymal stromal cell (MSC) therapies into clinical reality. Such procedures need to be developed and tailored not just for human MSCs, but also for those from animal species in areas like veterinary medicine and preclinical research.
The study focuses on equine adipose-derived mesenchymal stromal cells (AD-MSCs). These are cells isolated from the adipose (fat) tissue of horses, which have certain abilities like differentiation and self-renewal, making them a focus of many therapeutic and scientific research.
Role of Equine Platelet Lysate in Cell Culture
Equine platelet lysate (ePL) is an alternative to fetal bovine serum (FBS), a supplement often used in cell culture. The ePL was previously found to support the proliferation and basic characteristics of equine AD-MSCs.
In this study, the effects of ePL on the functional properties of AD-MSCs were further analyzed, with a focus on cell fitness, genetic stability, and pro-angiogenic potency – i.e., the capacity to promote new blood vessel formation.
Findings and Conclusions
AD-MSCs cultured with 2.5% ePL showed increased rates of apoptosis (programmed cell death) and decreased senescence levels compared to those cultured with 10% ePL.
Non-clonal chromosomal aberrations (random changes in chromosome structure or number) occurred less frequently in AD-MSCs cultured with ePL than in those cultured with FBS, suggesting that ePL might promote greater genetic stability.
ePL was found to support the pro-angiogenic effects of the AD-MSCs. In the presence of ePL, the cells exhibited increased expression of the vascular endothelial growth factor (VEGF) receptor-2, a key protein involved in angiogenesis. Furthermore, the ePL and the AD-MSCs together promoted the growth of endothelial cells and led to the formation of vessel-like structures in some samples.
These findings suggest that ePL is not only a feasible substitute for FBS in equine AD-MSC culture media, but it could actually enhance the functional properties of the cells.
Cite This Article
APA
Hagen A, Niebert S, Brandt VP, Holland H, Melzer M, Wehrend A, Burk J.
(2022).
Functional properties of equine adipose-derived mesenchymal stromal cells cultured with equine platelet lysate.
Front Vet Sci, 9, 890302.
https://doi.org/10.3389/fvets.2022.890302
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
This article includes 74 references
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells.. Science 1999 Apr 2;284(5411):143-7.
Karnieli O, Friedner OM, Allickson JG, Zhang N, Jung S, Fiorentini D, Abraham E, Eaker SS, Yong TK, Chan A, Griffiths S, Wehn AK, Oh S, Karnieli O. A consensus introduction to serum replacements and serum-free media for cellular therapies.. Cytotherapy 2017 Feb;19(2):155-169.
van der Valk J, Brunner D, De Smet K, Fex Svenningsen A, Honegger P, Knudsen LE, Lindl T, Noraberg J, Price A, Scarino ML, Gstraunthaler G. Optimization of chemically defined cell culture media--replacing fetal bovine serum in mammalian in vitro methods.. Toxicol In Vitro 2010 Jun;24(4):1053-63.
Burnouf T, Strunk D, Koh MB, Schallmoser K. Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?. Biomaterials 2016 Jan;76:371-87.
European Medicines Agency London Committee for Medicinal Products for Human Use (CHMP). Guideline on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal. 2013.
Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F. Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation.. Biol Blood Marrow Transplant 2018 Nov;24(11):2365-2370.
Del Bue M, Riccò S, Conti V, Merli E, Ramoni R, Grolli S. Platelet lysate promotes in vitro proliferation of equine mesenchymal stem cells and tenocytes.. Vet Res Commun 2007 Aug;31 Suppl 1:289-92.
Caprio CP, Andrews CH. The Effect of Replacing Fetal Bovine Serum with Platelet Releasate on the Characterization of MSCs. Undergraduate Research Scholars Program 2018.
Vallés G, Bensiamar F, Crespo L, Arruebo M, Vilaboa N, Saldaña L. Topographical cues regulate the crosstalk between MSCs and macrophages.. Biomaterials 2015 Jan;37:124-33.
Luk F, Carreras-Planella L, Korevaar SS, de Witte SFH, Borràs FE, Betjes MGH, Baan CC, Hoogduijn MJ, Franquesa M. Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function.. Front Immunol 2017;8:1042.
Trojahn Kølle SF, Oliveri RS, Glovinski PV, Kirchhoff M, Mathiasen AB, Elberg JJ, Andersen PS, Drzewiecki KT, Fischer-Nielsen A. Pooled human platelet lysate versus fetal bovine serum-investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use.. Cytotherapy 2013 Sep;15(9):1086-97.
Skific M, Golemovic M, Crkvenac-Gornik K, Vrhovac R, Golubic Cepulic B. Comparative Analysis of Biological and Functional Properties of Bone Marrow Mesenchymal Stromal Cells Expanded in Media with Different Platelet Lysate Content.. Cells Tissues Organs 2018;205(4):226-239.
Mazurkevych A, Malyuk M, Bezdieniezhnykh N, Starodub L, Kharkevych Y, Brusko E. Immunophenotypic characterisation and cytogenetic analysis of mesenchymal stem cells from equine bone marrow and foal umbilical cords during in vitro culture. J Vet Res 2016 60:339–47.
Yong KW, Choi JR, Mohammadi M, Mitha AP, Sanati-Nezhad A, Sen A. Mesenchymal Stem Cell Therapy for Ischemic Tissues.. Stem Cells Int 2018;2018:8179075.
Levoux J, Prola A, Lafuste P, Gervais M, Chevallier N, Koumaiha Z, Kefi K, Braud L, Schmitt A, Yacia A, Schirmann A, Hersant B, Sid-Ahmed M, Ben Larbi S, Komrskova K, Rohlena J, Relaix F, Neuzil J, Rodriguez AM. Platelets Facilitate the Wound-Healing Capability of Mesenchymal Stem Cells by Mitochondrial Transfer and Metabolic Reprogramming.. Cell Metab 2021 Feb 2;33(2):283-299.e9.
Qian Y, Han Q, Chen W, Song J, Zhao X, Ouyang Y, Yuan W, Fan C. Platelet-Rich Plasma Derived Growth Factors Contribute to Stem Cell Differentiation in Musculoskeletal Regeneration.. Front Chem 2017;5:89.
Hersant B, Sid-Ahmed M, Braud L, Jourdan M, Baba-Amer Y, Meningaud JP, Rodriguez AM. Platelet-Rich Plasma Improves the Wound Healing Potential of Mesenchymal Stem Cells through Paracrine and Metabolism Alterations.. Stem Cells Int 2019;2019:1234263.
Becherucci V, Piccini L, Casamassima S, Bisin S, Gori V, Gentile F, Ceccantini R, De Rienzo E, Bindi B, Pavan P, Cunial V, Allegro E, Ermini S, Brugnolo F, Astori G, Bambi F. Human platelet lysate in mesenchymal stromal cell expansion according to a GMP grade protocol: a cell factory experience.. Stem Cell Res Ther 2018 May 2;9(1):124.
Viau S, Lagrange A, Chabrand L, Lorant J, Charrier M, Rouger K, Alvarez I, Eap S, Delorme B. A highly standardized and characterized human platelet lysate for efficient and reproducible expansion of human bone marrow mesenchymal stromal cells.. Cytotherapy 2019 Jul;21(7):738-754.
Kirsch M, Rach J, Handke W, Seltsam A, Pepelanova I, Strauß S, Vogt P, Scheper T, Lavrentieva A. Comparative Analysis of Mesenchymal Stem Cell Cultivation in Fetal Calf Serum, Human Serum, and Platelet Lysate in 2D and 3D Systems.. Front Bioeng Biotechnol 2020;8:598389.
Palombella S, Perucca Orfei C, Castellini G, Gianola S, Lopa S, Mastrogiacomo M, Moretti M, de Girolamo L. Systematic review and meta-analysis on the use of human platelet lysate for mesenchymal stem cell cultures: comparison with fetal bovine serum and considerations on the production protocol.. Stem Cell Res Ther 2022 Apr 4;13(1):142.
Losi P, Barsotti MC, Foffa I, Buscemi M, De Almeida CV, Fabbri M, Gabbriellini S, Nocchi F, Ursino S, Urciuoli P, Mazzoni A, Soldani G. In vitro human cord blood platelet lysate characterisation with potential application in wound healing.. Int Wound J 2020 Feb;17(1):65-72.
Tancharoen W, Aungsuchawan S, Markmee R, Narakornsak S, Pothacharoen P. The effects of human platelet lysate versus commercial endothelial growth medium on the endothelial differentiation potential of human amniotic fluid mesenchymal stem cells.. Heliyon 2020 Sep;6(9):e04873.
Burk J, Ribitsch I, Gittel C, Juelke H, Kasper C, Staszyk C, Brehm W. Growth and differentiation characteristics of equine mesenchymal stromal cells derived from different sources.. Vet J 2013 Jan;195(1):98-106.
McGowan-Jordan J, Hastings R, Moore S. Re: International System for Human Cytogenetic or Cytogenomic Nomenclature (ISCN): Some Thoughts, by T. Liehr.. Cytogenet Genome Res 2021;161(5):225-226.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.. Cytotherapy 2006;8(4):315-7.
Schallmoser K, Bartmann C, Rohde E, Bork S, Guelly C, Obenauf AC, Reinisch A, Horn P, Ho AD, Strunk D, Wagner W. Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions.. Haematologica 2010 Jun;95(6):867-74.
Neri S. Genetic Stability of Mesenchymal Stromal Cells for Regenerative Medicine Applications: A Fundamental Biosafety Aspect.. Int J Mol Sci 2019 May 15;20(10).
Søndergaard RH, Follin B, Lund LD, Juhl M, Ekblond A, Kastrup J, Haack-Sørensen M. Senescence and quiescence in adipose-derived stromal cells: Effects of human platelet lysate, fetal bovine serum and hypoxia.. Cytotherapy 2017 Jan;19(1):95-106.
Carr BI, Cavallini A, D'Alessandro R, Refolo MG, Lippolis C, Mazzocca A, Messa C. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro.. BMC Cancer 2014 Jan 27;14:43.
Roemeling-van Rhijn M, de Klein A, Douben H, Pan Q, van der Laan LJ, Ijzermans JN, Betjes MG, Baan CC, Weimar W, Hoogduijn MJ. Culture expansion induces non-tumorigenic aneuploidy in adipose tissue-derived mesenchymal stromal cells.. Cytotherapy 2013 Nov;15(11):1352-61.
Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms.. Cancer Res 2007 Oct 1;67(19):9142-9.
Zaman WS, Makpol S, Sathapan S, Chua KH. Long-term in vitro expansion of human adipose-derived stem cells showed low risk of tumourigenicity.. J Tissue Eng Regen Med 2014 Jan;8(1):67-76.
Schallmoser K, Rohde E, Reinisch A, Bartmann C, Thaler D, Drexler C, Obenauf AC, Lanzer G, Linkesch W, Strunk D. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum.. Tissue Eng Part C Methods 2008 Sep;14(3):185-96.
Kwon HM, Hur SM, Park KY, Kim CK, Kim YM, Kim HS, Shin HC, Won MH, Ha KS, Kwon YG, Lee DH, Kim YM. Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis.. Vascul Pharmacol 2014 Oct;63(1):19-28.
Gangadaran P, Rajendran RL, Lee HW, Kalimuthu S, Hong CM, Jeong SY, Lee SW, Lee J, Ahn BC. Extracellular vesicles from mesenchymal stem cells activates VEGF receptors and accelerates recovery of hindlimb ischemia.. J Control Release 2017 Oct 28;264:112-126.
Goerke SM, Plaha J, Hager S, Strassburg S, Torio-Padron N, Stark GB, Finkenzeller G. Human endothelial progenitor cells induce extracellular signal-regulated kinase-dependent differentiation of mesenchymal stem cells into smooth muscle cells upon cocultivation.. Tissue Eng Part A 2012 Dec;18(23-24):2395-405.
Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro.. Stem Cells 2004;22(3):377-84.
Haack-Sorensen M, Friis T, Bindslev L, Mortensen S, Johnsen HE, Kastrup J. Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell therapy.. Scand J Clin Lab Invest 2008;68(3):192-203.
Chiaverina G, di Blasio L, Monica V, Accardo M, Palmiero M, Peracino B, Vara-Messler M, Puliafito A, Primo L. Dynamic Interplay between Pericytes and Endothelial Cells during Sprouting Angiogenesis.. Cells 2019 Sep 19;8(9).
Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, Drexler C, Lanzer G, Linkesch W, Strunk D. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells.. Transfusion 2007 Aug;47(8):1436-46.
Moellerberndt J, Niebert S, Fey K, Hagen A, Burk J. Impact of platelet lysate on immunoregulatory characteristics of equine mesenchymal stromal cells. Front Vet Sci 2024;11:1385395.